Evaluation of PD 0348292 for Preventing Blood Clots in th... | NCT00306254 | Trialant

Evaluation of PD 0348292 for Preventing Blood Clots in th... | NCT00306254 | Trialant

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
The primary efficacy endpoint is the incidence of total venous thromboembolism (including all proximal and distal deep vein thrombosis [DVT] and pulmonary embolism [PE])
The primary safety endpoint is the incidence of total bleeding.

Secondary Outcomes

Measure	Description	Time Frame
Secondary efficacy endpoints are incidence of proximal DVT, distal DVT, and PE.
Secondary safety endpoints are incidence of major and minor bleeding, all-cause mortality, abnormal liver function test elevation, adverse events and serious adverse events, and changes in clinical laboratory parameters.

Contacts/Locations Module